The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie
CAR-T Therapy
| Regimen Name |
Indication |
|
Axicabtagene ciloleucel (Yescarta®) (CAR-T) DLBCL and PMBCL
Regimen
|
00717a
Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.
|
|
Fludarabine & cycloPHOSphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)
Regimen
|
00608a
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy with axicabtagene ciloleucel (Yescarta®) in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.
|
|
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL
Regimen
|
00606a
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy
|
|
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL
Regimen
|
00607a
Lymphodepleting chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients aged 18-25 years with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse
|
| |
|
|
Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL
Regimen
|
00687a
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
|
|
Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL
Regimen
|
00686a
Treatment of young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse
|
| |
|
